Circulating Tumor Cell Eradication as an Intermediate Efficacy End Point for Metastatic Castration-Resistant Prostate Cancer: Is There Enough Evidence?
- PMID: 29272163
- DOI: 10.1200/JCO.2017.76.5487
Circulating Tumor Cell Eradication as an Intermediate Efficacy End Point for Metastatic Castration-Resistant Prostate Cancer: Is There Enough Evidence?
Comment on
-
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.J Clin Oncol. 2018 Feb 20;36(6):572-580. doi: 10.1200/JCO.2017.75.2998. Epub 2017 Dec 22. J Clin Oncol. 2018. PMID: 29272162 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
